**Indication**
Bacterial infection of joint  
*ICD11 code: FA10.0*

**INN**
Clindamycin

**Medicine type**
Chemical agent

**Antibiotic groups**
ACCESS

**List type**
Core

**Formulations**
- Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate) (EML); 900 mg per 6 mL (as phosphate) (EML)
- Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) (EMLc)
- Oral > Solid: 150 mg (as hydrochloride)

**EML status history**
- First added in 2017 (TRS 1006)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
All

**Age**
Also recommended for children

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**
Clindamycin

**DrugBank**
Clindamycin

---

**Expert Committee recommendation**

The Expert Committee recommended the inclusion of a new strength, child-friendly dispersible tablet formulation of amoxicillin + clavulanic acid (200 mg + 28.5 mg) as an Access group antibiotic on the core list of the EMLc for treatment of bacterial infections in children – specifically those infections for which amoxicillin + clavulanic acid is already recommended on the EMLc. The Committee noted that the 7:1 ratio of amoxicillin to clavulanic acid is associated with similar efficacy to the 4:1 ratio but has a reduced frequency of gastrointestinal adverse effects. The Committee endorsed the importance of age-appropriate formulations to better meet the dosing needs of children. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of a new formulation of amoxicillin + clavulanic acid (dispersible tablet 250 mg + 62.5 mg) to the EMLc.
- the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc.
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc.
- the addition of new strength formulations of cloxacillin (capsule 250 mg, powder for injection 250 mg (as sodium) and powder for oral liquid 250 mg/5 mL (as sodium) on the EMLc.

**EML recommendations: Bacterial infection of joint**

**First choice**

**Second choice**
<table>
<thead>
<tr>
<th>cloxacillin</th>
<th>cefazolin</th>
</tr>
</thead>
<tbody>
<tr>
<td>clindamycin</td>
<td>amoxicillin + clavulanic acid</td>
</tr>
<tr>
<td>cefotaxime</td>
<td>ceftriaxone</td>
</tr>
</tbody>
</table>